lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
Lupus Science & Medicine

Prognostic value of baseline clinical features in SLE: a cluster analysis

Objective SLE is a heterogeneous systemic autoimmune disease with diverse clinical manifestations. We aimed to identify ...
lupus.bmj

Genetic determinants of childhood onset systemic lupus erythematosus

Introduction Childhood-onset systemic lupus erythematosus (cSLE) is associated with significant morbidity and mortality. While numerous variants have been associated with adult-onset SLE, limited data ...
lupus.bmj

Belimumab induces early and sustained resolution of lupus thrombocytopenia

Objective Belimumab has well-established efficacy in improving overall SLE disease activity and preventing flares and organ damage. Belimumab effects have been demonstrated across organ domains but ...
lupus.bmj

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ...

Objective To determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered mosunetuzumab, a CD20xCD3 T-cell-engaging bispecific antibody, in ...
lupus.bmj

Stage-resolved mapping of RP105 (CD180)-negative B cells reveals residual plasmablast-lineage skewing in SLE: a cross-sectional study

Objective To determine whether clinically inactive/low-activity SLE reflects immunological remission in this cross-sectional study using CD180 (RP105)-anchored, stage-resolved profiling of peripheral ...
lupus.bmj

PO:08:209 Safety and efficacy of rituximab to manage pregnancy-related severe flare of systemic lupus erythematosus with new onset lupus nephritis: a case report

We present the case of a 34-year-old with SLE treated initially with hydroxychloroquine (200 mg/daily) and low dose of glucocorticoids(GC). The autoimmune profile revealed positivity for ...
lupus.bmj

15 LLDAS and DORIS remission redefined or refined: the rheumatologist’s perspective

Low disease activity and remission are recognized as important goals in the treatment of patients with lupus and as valuable outcomes in epidemiological research and in clinical trials. The former is ...
lupus.bmj

Langerhans cells infiltration in lymph nodes of patients with systemic lupus erythematosus

Objective This study aimed to characterise the clinical features and treatment regimens of patients with lupus who have lymphadenopathy (LAP), as well as to investigate the presence and potential ...
lupus.bmj

Glucocorticoid tapering early in the course of juvenile SLE: association with lupus low disease activity state and outcomes

Objective To determine the feasibility and risk of flares by achieving successful glucocorticoid (GC) tapering during the first year of juvenile SLE and the value of early achievement of childhood ...